NORAD: Non-coding RNA activated by DNA damage (G647979)

Target Name: NORAD

NCBI ID: G647979

NORAD

Other Name(s): Non-coding RNA activated by DNA damage | LINC00657 | non-coding RNA activated by DNA damage | Long intergenic non-protein coding RNA 657

NORAD: Non-coding RNA activated by DNA damage

NORAD (Non-coding RNA activated by DNA damage) is a protein that plays a crucial role in the regulation of gene expression in the cell. It is a non-coding RNA molecule that is produced in response to DNA damage, and it has been shown to have a wide range of functions in various cellular processes.

The discovery and characterization of NORAD

NORAD was first identified as a new gene in the human genome using the transcriptome array technology. The gene was found to encode a protein that was different from typical RNA molecules, as it had a predicted RNA structure and was expressed in a cell-type-specific manner.

Subsequent studies showed that NORAD was involved in the regulation of gene expression in various cellular processes, including cell growth, apoptosis, and DNA repair. It was also found to play a role in the development and progression of certain diseases, such as cancer.

The biology of NORAD

NORAD is a non-coding RNA molecule that is produced in response to DNA damage. When a cell experiences DNA damage, such as a double strand break or an insertion/deletion, NORAD is activated and begins to transcribe mRNA.

The generated mRNA is then translated into a protein that plays a role in repairing the damaged DNA. This protein is composed of multiple domains, including a T-DNA binding domain, a GFP-like domain, and a C-terminal domain that contains a leucine-rich repeat.

The T-DNA binding domain is responsible for binding to DNA and allowing the protein to enter the damaged site. The GFP-like domain is a protein that is involved in the signaling of gene expression, and the C-terminal domain contains the leucine-rich repeat, which is a common feature of proteins that contain multiple leucine amino acids.

In addition to its role in DNA repair, NORAD has also been shown to play a role in cell growth and apoptosis. It has been shown to promote the growth of certain cell types and to be involved in the regulation of cell death.

The clinical significance of NORAD

The discovery of NORAD has significant implications for the treatment of various diseases. Since NORAD has been shown to be involved in the regulation of gene expression in various cellular processes, it may be a potential drug target or biomarker.

For example, the regulation of NORAD has been shown to be involved in the development and progression of certain diseases, such as cancer. Therefore, inhibitors of NORAD may be a promising new approach to cancer treatment.

In addition, the regulation of NORAD has also been shown to be involved in the regulation of cell growth and apoptosis. Therefore, inhibitors of NORAD may be a promising new approach to the treatment of certain diseases, such as cardiovascular disease and neurodegenerative diseases.

Conclusion

NORAD is a non-coding RNA molecule that is produced in response to DNA damage. It has been shown to play a role in the regulation of gene expression in various cellular processes, including cell growth, apoptosis, and DNA repair. The discovery and characterization of NORAD has significant implications for the treatment of various diseases. Therefore, further research is needed to fully understand the role of NORAD in these cellular processes and to develop new treatments based on its properties.

Protein Name: Non-coding RNA Activated By DNA Damage

The "NORAD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NORAD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets